Clinical trials: Human Brain and Cognition
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Alzheimer's Disease
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
The purpose of this study is to demonstrate that donepezil slows the progression of Alzheimer's disease (AD) using magnetic resonance imaging (MRI) of the brain to measure the volume of the hippocampus in patients with…
- Trial name
- NCT00403520
- Testing
- Experimental 1
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Parkinson's Disease, PD
iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- Parkinson's Disease, PD, Mild Cognitive Impairment, MCI
- Trial name
- iPACES-PD (NCT05810454)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC
Huntington Disease
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
- Trial name
- NCT02907294
- Testing
- PBF-999 / 160 mg, PBF-999 / 320 mg
- Where
- Spain
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Mild Cognitive Impairment
Effect of Consuming a Mixture of Extracts and DHA on the Mild Cognitive Impairment
The objective of this trial is to evaluate the effect of the consumption of a mixture of extracts and DHA on the mild cognitive impairment.
- Trial name
- NCT06254040
- Testing
- mixture of extracts and DHA
- Where
- Spain
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Alzheimer Disease, Mild Cognitive Impairment
A Study of NTRX-07 in Participants With Alzheimer's Disease
1. Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07.
- Trial name
- SPPN-AD (NCT07058688)
- Testing
- NTRX-07
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 48 people
- Sponsor
- NeuroTherapia, Inc.
Huntington Disease
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
- Trial name
- NCT04514367
- Testing
- ANX005
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Annexon, Inc.
Dementia
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.
- Trial name
- NCT00887601
- Testing
- MK3134, Donepezil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Huntington Disease
Efficacy and Safety of NestaCell® in Huntington's Disease
Huntington's disease (HD) is a rare neurodegenerative condition caused by increased CAG trinucleotide repeats in the HTT gene, on chromosome 4. The estimated global prevalence is 2.71 cases per 100,000 inhabitants.
- Trial name
- STAR (NCT06097780)
- Testing
- NestaCell®
- Volunteers
- 120 people
- Sponsor
- Azidus Brasil
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Cognition Disorder
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856
The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers.
- Trial name
- NCT05077501
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Mild Cognitive Impairment, Alzheimer's Disease
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders
- Trial name
- NCT01745198
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Pamlab, Inc.
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Cognitive Decline, Cognitive Impairment, Mild
Efficacy of a Mobile-based Multidomain Intervention to Improve Cognitive Function and Health-related Outcomes Among Older Korean Adults With a High Risk of Dementia
This study investigated the efficacy of the Silvia program, a mobile-based multidomain intervention, to improve cognitive function and health-related outcomes of older adults with a high risk of dementia.
- Conditions
- Cognitive Decline, Cognitive Impairment, Mild, Aging, Dementia
- Trial name
- NCT05675137
- Testing
- mobile-based, paper-based
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Silvia Health
Cognition, Multiomics
Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults
This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults.
- Conditions
- Cognition, Multiomics, Microbiome Analysis, Metabolome
- Trial name
- PROFILE (NCT07457242)
- Testing
- Probiotic Supplementation (Lactobacillus plantarum)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- OneCarbon
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Vascular Dementia, Mild Cognitive Impairment
Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
This clinical trial evaluates the preliminary effectiveness and safety of Cerogrin, a medical device developed by Neurogrin Inc.
- Trial name
- NCT07149038
- Testing
- Cerogrin
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Neurogrin Inc.